Crisaborole clinical trials
Crisaborole is named as an intervention in 2 current clinical trials in our Egypt register. 1 is recruiting patients now. All registered phases are Phase 3. The lead sponsor is Cairo University. The most-studied condition is Psoriasis.
Where Crisaborole is approved
All regulators →Of the three regulators tracked here, the first to approve Crisaborole was the US, on 14 Dec 2016. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Crisaborole patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Crisaborole, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 4 listed patents; the last listed expires 20 Jul 2030 (US 8168614, including a 6-month paediatric extension).
- Latest patent on the drug substance itself: 29 Dec 2029 (US 8039451, with paediatric extension).
Reproduced from the FDA Orange Book and Purple Book (checked 26 Oct 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Crisaborole
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
NICE appraisals of Crisaborole
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Crisaborole. 1 is current.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) NICE TA701 | Terminated (no company submission) | 19 May 2021 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Crisaborole
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Crisaborole
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.
NCT07904910 · ClinicalTrials.gov ↗ · Vitiligo, Non-Segmental Vitiligo (NSV), Stable Vitiligo
|
Phase 3 | Recruiting | Cairo University | Egypt |
|
Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis.
NCT07892339 · ClinicalTrials.gov ↗ · Psoriasis, Psoriasis Genital
|
Phase 3 | Not yet open | Cairo University | Egypt |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Crisaborole
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Cairo University | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Egypt | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Crisaborole trials
How many clinical trials are testing Crisaborole?
2 current trials in our Egypt register name Crisaborole as a drug or biological intervention, as of the registry sync on 30 October 2026. Completed and withdrawn studies are not counted.
Are Crisaborole trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Crisaborole clinical trials?
The lead sponsor is Cairo University. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Crisaborole works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Crisaborole works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Crisaborole (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 30 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.